MIAMI, FL / ACCESSWIRE / January 26, 2021 / VitanaX, Inc. (OTC PINK:VITX), a provider of comprehensive programs for greater well-being, fitness and health with a wellness network marketing program, is pleased to provide its plan to make its products available in the U.S.
Vitana-X has engaged with a law firm to apply for its FDA submission to gain approval to distribute its products in the U.S.
The Company's patented micellization technology allows for pure products of plant nature, such as curcumin, hemp, omega 369 and the most important vitamins B, C, D and E in water soluble form and highest organic availability. This creates a differentiated value-add for Vitana-X products.
In anticipation of its U.S. launch, partners are currently being trained and prepared for the U.S market.
Alois Anichhofer, Chief Executive Officer of VitanaX Inc, commented, "the U.S. market will become one of our most important and concentrated markets in 2021 based on its massive buying power. We are also exploring to produce and manufacture our products directly in the U.S in future."
Vitana-X, Inc.'s (OTC: VITX) Vitana-X, an international wellness company specializing in the development and manufacture of health-promoting products based on DNA analysis. As a pioneer in this industry and a worldwide network of highly qualified experts, it offers its customers extensive opportunities to lead a healthier life. Vitana-X offers comprehensive programs for greater well-being, fitness and health by helping you achieve the desired results and offering exercises that fit your body type. Vitana-X wants to support people in their healthy development and be their reliable partner for their full potential. Vitana-X comes from two worlds and wants to unite them in the future - science and the challenges of daily life, so that its customers can continue to care for other areas of life without sacrificing a healthy life.
For additional information on Vitana-X, please visit: https://vitanax.net/en/
Forward-Looking Statements. This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act") (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words "believe," "anticipate," "estimate," "expect," "intend," "plan," "project," "prospects," "outlook," and similar words or expressions, or future or conditional verbs such as "will," "should," "would," "may," and "could" are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance or achievements to be materially different from any anticipated results, performance or achievements. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company's forward-looking statements, please see the Company's Form 10-K filed on December 28, 2019, for the fiscal year ended September 30, 2018, including but not limited to the discussion under "Risk Factors" therein, which the Company has filed with the SEC and which may be viewed at http://www.sec.gov.
SOURCE: VitanaX, Inc.